Published research on Artemisinin
4 peer-reviewed publications on Artemisinin in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
In 23 metastatic breast cancer patients, oral artesunate as add-on therapy for four weeks was reported to be safe and well tolerated, with dose-limiting adverse events not exceeding 33 percent at any dose level.
- Clinical trial
In 20 colorectal cancer patients who completed this pilot trial, preoperative oral artesunate was reported to show anti-proliferative effects (Bayesian probability 0.89 of reduced Ki67) and was generally well tolerated, with 1 recurrence in the artesunate group versus 6 in the placebo group over a median 42-month follow-up.
- Review
From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy
This overview of two decades of literature reported that artemisinin and its derivatives (dihydroartemisinin, artesunate, artemether, arteether) acted against cancer cells through oxidative stress, DNA damage, multiple cell death modes and inhibition of angiogenesis and signalling pathways, with case reports and pilot phase I/II trials indicating clinical activity and hepatotoxicity cases noted in combination with complementary medicines.
- In vitro
Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells
Across the NCI panel of 60 tumour cell lines, expression of 20 iron-related genes correlated with cytotoxicity of ten artemisinin derivatives, and the ferroptosis inhibitor ferrostatin-1 and the iron chelator deferoxamine reduced the cytotoxicity of dihydroartemisinin, indicating ferroptosis as the cell death mode.
Artemisinin in the catalog (specifications, pack sizes, Certificate of Analysis)